Toxicity and disease recurrence are common in patients with non-muscle-invasive bladder cancer (NMIBC) treated with intravesical BCG. Results from a prospective randomized trial in 407 patients with NIMBC show that sequential treatment with mitomycin C and BCG increased the disease-free interval compared with BCG alone (HR = 0.57) and reduced the relapse rate by 13.3%. However, higher toxicity might restrict its use to patients with a high probability of recurrence.
References
Solsona, E. et al. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. Eur. Urol. 10.1016/j.eururo.2014.09.026
Rights and permissions
About this article
Cite this article
Sequential mitomycin C and BCG decreases relapse rate. Nat Rev Urol 11, 660 (2014). https://doi.org/10.1038/nrurol.2014.296
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.296
